Alok Swaroop

524 total citations
21 papers, 328 citations indexed

About

Alok Swaroop is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Alok Swaroop has authored 21 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Hematology and 6 papers in Genetics. Recurrent topics in Alok Swaroop's work include Acute Myeloid Leukemia Research (6 papers), Epigenetics and DNA Methylation (5 papers) and Protein Degradation and Inhibitors (5 papers). Alok Swaroop is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Epigenetics and DNA Methylation (5 papers) and Protein Degradation and Inhibitors (5 papers). Alok Swaroop collaborates with scholars based in United States, India and Australia. Alok Swaroop's co-authors include Catalina Troche, Jonathan D. Licht, Richard L. Bennett, Douglas Forrest, Ailing Lu, Lily Ng, David S. Sharlin, Anand Swaroop, Yang Liu and Andy H. Vo and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and Blood.

In The Last Decade

Alok Swaroop

18 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alok Swaroop United States 6 251 52 38 35 33 21 328
Nicholas Stong United States 11 330 1.3× 60 1.2× 53 1.4× 22 0.6× 12 0.4× 28 471
Ana Arteche‐López Spain 9 172 0.7× 22 0.4× 14 0.4× 22 0.6× 28 0.8× 23 262
Claude Shelton United States 6 275 1.1× 64 1.2× 33 0.9× 83 2.4× 19 0.6× 7 331
Alexandra Pietraszkiewicz United States 6 174 0.7× 21 0.4× 25 0.7× 23 0.7× 15 0.5× 8 306
Elodie Sanchez France 9 159 0.6× 25 0.5× 42 1.1× 21 0.6× 6 0.2× 15 272
Dongmin Gu United States 12 356 1.4× 37 0.7× 48 1.3× 85 2.4× 18 0.5× 16 419
Michael Reimer United States 10 270 1.1× 27 0.5× 25 0.7× 25 0.7× 28 0.8× 15 346
Kelly Arndt United States 10 255 1.0× 45 0.9× 43 1.1× 45 1.3× 38 1.2× 17 378
Thien N. Sam United States 6 202 0.8× 161 3.1× 40 1.1× 11 0.3× 8 0.2× 7 310
Tony Brooks United Kingdom 9 272 1.1× 57 1.1× 42 1.1× 22 0.6× 6 0.2× 15 386

Countries citing papers authored by Alok Swaroop

Since Specialization
Citations

This map shows the geographic impact of Alok Swaroop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alok Swaroop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alok Swaroop more than expected).

Fields of papers citing papers by Alok Swaroop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alok Swaroop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alok Swaroop. The network helps show where Alok Swaroop may publish in the future.

Co-authorship network of co-authors of Alok Swaroop

This figure shows the co-authorship network connecting the top 25 collaborators of Alok Swaroop. A scholar is included among the top collaborators of Alok Swaroop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alok Swaroop. Alok Swaroop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Swaroop, Alok & Feng Yue. (2025). Chromatin hubs drive key regulatory networks in leukemia. Molecular Cell. 85(1). 1–2.
2.
3.
Luan, Yu, Ye Hou, Qiushi Jin, et al.. (2025). Abstract 2749: Single-cell 3D genome structure analysis reveals clonal evolution and heterogeneity in acute myeloid leukemia. Cancer Research. 85(8_Supplement_1). 2749–2749. 1 indexed citations
4.
Abaza, Yasmin, Eric S. Winer, Guru Subramanian Guru Murthy, et al.. (2024). Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers. American Journal of Hematology. 99(4). 606–614. 12 indexed citations
5.
6.
Ruan, Jia, Jasmine M. Zain, Borko Jovanovic, et al.. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances. 7(19). 5771–5779. 19 indexed citations
7.
Swaroop, Alok, Diana Saleiro, & Leonidas C. Platanias. (2023). Interferon and myeloproliferative neoplasms: Evolving therapeutic approaches. BioEssays. 45(3). e2200203–e2200203.
8.
Shallis, Rory M., Eric S. Winer, Talha Badar, et al.. (2022). Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML). Blood. 140(Supplement 1). 8921–8922. 2 indexed citations
9.
Li, Jianping, Priscillia Lhoumaud, Alberto Riva, et al.. (2021). Dysregulation of Epigenetic Landscape Uncovered the Mechanisms Underlying the Relapse of Pediatric Acute Lymphoblastic Leukemia with NSD2 Mutation. Blood. 138(Supplement 1). 3297–3297. 1 indexed citations
10.
Ruan, Jia, Jasmine M. Zain, Borko Jovanovic, et al.. (2021). Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).. Journal of Clinical Oncology. 39(15_suppl). 7514–7514. 5 indexed citations
11.
Ruan, Jia, Jasmine Zain, Borko Jovanovic, et al.. (2021). MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA (PTCL). Hematological Oncology. 39(S2). 3 indexed citations
12.
Li, Jianping, Daphné Dupéré-Richer, Alok Swaroop, et al.. (2020). NSD2-E1099K Mutation Leads to Glucocorticoid-Resistant B Cell Lymphocytic Leukemia in Mice. Blood. 136(Supplement 1). 3–4. 1 indexed citations
13.
Swaroop, Alok, Jon A. Oyer, Christine Will, et al.. (2018). An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene. 38(5). 671–686. 36 indexed citations
14.
Li, Jianping, Catalina Troche, Alok Swaroop, et al.. (2018). A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance of Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 653–653. 4 indexed citations
15.
Bennett, Richard L., Alok Swaroop, Catalina Troche, & Jonathan D. Licht. (2017). The Role of Nuclear Receptor–Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. Cold Spring Harbor Perspectives in Medicine. 7(6). a026708–a026708. 124 indexed citations
16.
Bumb, R A, et al.. (2017). Disseminated Herpes Zoster with Meningo-encephalitis.. PubMed. 55(4). 256–257. 1 indexed citations
17.
Vo, Andy H., et al.. (2013). Loss of Fibrinogen in Zebrafish Results in Symptoms Consistent with Human Hypofibrinogenemia. PLoS ONE. 8(9). e74682–e74682. 44 indexed citations
18.
Liu, Yang, Colin A. Kretz, Morgan L. Maeder, et al.. (2013). A Zebrafish Model Of Antithrombin III Deficiency Displays Bleeding and Thrombosis Secondary To Disseminated Intravascular Coagulation. Blood. 122(21). 200–200. 1 indexed citations
19.
Ng, Lily, Ailing Lu, Alok Swaroop, et al.. (2011). Two Transcription Factors Can Direct Three Photoreceptor Outcomes from Rod Precursor Cells in Mouse Retinal Development. Journal of Neuroscience. 31(31). 11118–11125. 71 indexed citations
20.
Sharma, Pratibha, et al.. (1993). Study of serum amylase in acute viral hepatitis.. PubMed. 41(3). 136–7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicholas Stong Breakdown of academic impact, for papers by Ana Arteche‐López Breakdown of academic impact, for papers by Claude Shelton Breakdown of academic impact, for papers by Alexandra Pietraszkiewicz Breakdown of academic impact, for papers by Elodie Sanchez Breakdown of academic impact, for papers by Dongmin Gu Breakdown of academic impact, for papers by Michael Reimer Breakdown of academic impact, for papers by Kelly Arndt Breakdown of academic impact, for papers by Thien N. Sam Breakdown of academic impact, for papers by Tony Brooks
Rankless by CCL
2026